Mark Hamilton, MD
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2018 | Baylor College of Medicine, Houston, TX, US, Doctor of Medicine |
| 2016 | Baylor College of Medicine, Houston, TX, US, Doctor of Philosophy (Molecular and Cellular Biology) |
| 2005 | Austin College, Sherman, Texas, US, Bachelor of Arts |
Postgraduate Training
| 2024-2025 | Bone Marrow Transplantation/Cellular Therapy Fellowship, Stanford, Stanford, California |
| 2021-2025 | Post-doctoral Research, Stanford, Stanford, California |
| 2020-2025 | Hematology/Oncology Fellowship, Stanford, Stanford, California |
| 2018-2020 | Internal Medicine Residency, Stanford, Stanford, California |
| 2011-2016 | Graduate Research, Baylor College of Medicine, Houston, Texas |
| 2011-2018 | Baylor College of Medicine Research Advocates for Student Scholars, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2024 | Board Certified in Oncology |
| 2024 | Board Certified in Hematology |
| 2021 | Board Certified in Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Brain Lab Mentor, Baylor College of Medicine, Houston, Texas, 2013 - 2015
Volunteer Staff, Quirrel Creek Ranch and Camp Periwinkle retreats, Houston, Texas, 2013 - 2017
Student Operating Committee, Baylor College Of Medicine, Houston, Texas, 2009 - 2016
Teaching Assistant, Baylor College of Medicine Graduate School of Biomedical Sciences, Houston, Texas
Extramural Institutional Committee Activities
Hosting & Conducting applicant interviews, BCM MSTP Program Student Operating Committee, Baylor College of Medicine, 2009 - 2016
Honors & Awards
| 2025 - 2027 | American Society for Transplantation and Cellular Therapy New Investigator Award |
| 2024 - Present | Best Abstracts Award, ASTCT Tandem |
| 2024 - Present | 2024 American Society of Hematology and Abstract Achievement Award, American Society of Hematology |
| 2024 - Present | Best scientific output in fellowship class |
| 2023 - Present | Stanford Department of Hematology Steve Coutre Award |
| 2023 - Present | Best Abstract Award, American Society of Hematology |
| 2022 - 2025 | Leukemia and Lymphoma Society Fellow Award |
| 2017 - Present | Department of Molecular and Cellular Biology Outstanding Graduate Award |
| 2012 - Present | Baylor College of Medicine Anthony R. Means Award for Academic Excellence |
| 2012 - Present | Baylor College of Medicine Trenton Award for Academic Excellence |
Selected Presentations & Talks
National Presentations
- 2025. Determinants of Post-CAR Myeloid Neoplasms Evolving after Lymphoma Therapy. Invited. Tandem Meetings, US.
- 2024. Damage to engineered T cell genomes. Invited. ASH 2024 Education Program, US.
- 2024. Single institution analysis of lymphoma treatment related post-CAR myeloid neoplasms. Invited. ASH, US.
- 2024. Absence of Evidence for Pervasive CAR19 Driven T-Cell Lymphomagenesis Revealed by Comprehensive Genomic Profiling of an Index Tumor. Invited. Tandem Meetings, US.
- 2024. Comprehensive genetic profiling of a post-CAR19 T-cell lymphoma does not reveal CAR-mediated tumorigenesis. Invited. Tandem Meetings, US.
- 2024. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Invited. Tandem Meetings, US.
- 2023. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Invited. ASH, US.
- 2023. Immune phenotypic quantification of axicabtagene ciloleucel and brexucabtagene autoleucel demonstrates lymphoma histology specific differences in CAR19 expansion and toxicity. Invited. Tandem Meetings, US.
Selected Publications
Peer-Reviewed Articles
- Li, X, Singhal, K, Deng, Q, Chihara, D, Russler-Germain, D, Harkins, RA, Henderson, J, Arita, K, Kizhakeyil, A, Sun, R, Lakra, P, Hussein, UK, Foltz, JA, Wilson, A, Schmidt, E, Nizamuddin, I, Dinh, T, Kesaraju, A, Hamilton, MP, Allen, CE, Gandhi, MK, Tobin, J, Jiang, A, Hilton, L, Scott, DW, Vega Vazquez, F, Flowers, CR, Westin, JR, Griffith, OL, Fehniger, TA, Griffith, M, Green, M. Large B cell lymphoma microenvironment archetype profiles. Cancer cell 43(7):1347-1364.e13, 2025. e-Pub 2025.
- Su YJ, Kramer AM, Hamilton MP, Agarwal N, Srinagesh HK, Baird JH, Sahaf B, Kuo A, Ehlinger ZJ, Desai MH, Rietberg SP, Tunuguntla R, Patel S, Chinnasamy H, Gkitsas-Long N, Klysz DD, Brown AK, Bharadwaj S, Dahiya S, Smith M, Muffly L, Mackall CL, Good Z, Feldman SA, Miklos DB, Frank MJ. Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL, 2025. PMID: 39775812.
- Su YJ, Kramer AM, Hamilton MP, Agarwal N, Srinagesh HK, Baird JH, Sahaf B, Kuo A, Ehlinger ZJ, Desai MH, Rietberg SP, Tunuguntla R, Patel S, Chinnasamy H, Gkitsas-Long N, Klysz DD, Brown AK, Bharadwaj S, Dahiya S, Smith M, Muffly L, Mackall CL, Good Z, Feldman SA, Miklos DB, Frank MJ. Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL. Cancer Discov 15(4):733-747, 2025. e-Pub 2025. PMID: 39775812.
- Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood 144(16):1689-1698, 2024. e-Pub 2024. PMID: 38968138.
- Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Oak JS, Younes SF, Natkunam Y, Hamilton MP, Su YJ, Agarwal N, Chinnasamy H, Egeler E, Mavroukakis S, Feldman SA, Sahaf B, Mackall CL, Muffly L, Miklos DB. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404(10450):353-363, 2024. e-Pub 2024. PMID: 38996463.
- Bharadwaj S, Lau E, Hamilton MP, Goyal A, Srinagesh H, Jensen A, Lee D, Mallampet J, Elkordy S, Syal S, Patil S, Latchford T, Sahaf B, Arai S, Johnston LJ, Lowsky R, Negrin R, Rezvani AR, Shizuru J, Meyer EH, Shiraz P, Mikkilineni L, Weng W, Smith M, Sidana S, Muffly L, Maecker HT, Frank MJ, Mackall C, Miklos D, Dahiya S. Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. J Immunother Cancer, 2024. e-Pub 2024. PMID: 38955420.
- Hamilton, MP, Craig, E, Sanchez, CG, Mina, A, Tamaresis, J, Kirmani, N, Ehlinger, ZJ, Syal, S, Good, Z, Sworder, BJ, Schroers-Martin, J, Lu, Y, Muffly, LS, Negrin, R, Arai, S, Lowsky, R, Meyer, E, Rezvani, A, Shizuru, JA, Weng, WK, Shiraz, P, Sidana, S, Bharadwaj, S, Smith, M, Dahiya, S, Sahaf, B, Kurtz, DM, Mackall, C, Tibshirani, R, Alizadeh, AA, Frank, MJ, Miklos, D. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances 8(12):3314-3326, 2024. e-Pub 2024. PMID: 38498731.
- Hamilton MP, Sugio T, Noordenbos T, L Bulterys SSP, Liu CL, Kang X, Zinaida Good MNO, Dahiya S, Frank MJ, Sahaf B, Dita Gratzinger CLM, Diehn M, Alizadeh AA, Miklos DB. Risk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy. New England Journal of Medicine 390(22):2047-2060, 2024. e-Pub 2024.
- Hamilton, MP, Sugio, T, Noordenbos, T, Shi, S, Bulterys, PL, Liu, CL, Kang, X, Olsen, M, Good, Z, Dahiya, S, Frank, MJ, Sahaf, B, Mackall, C, Gratzinger, D, Diehn, M, Alizadeh, AA, Miklos, D. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. New England Journal of Medicine 390(22):2047-2060, 2024. e-Pub 2024. PMID: 38865660.
- Schultz, LM, Jeyakumar, N, Kramer, AM, Sahaf, B, Srinagesh, H, Shiraz, P, Agarwal, N, Hamilton, MP, Erickson, C, Jacobs, A, Moon, J, Baggott, C, Arai, S, Bharadwaj, S, Johnston, L, Liedtke, M, Lowsky, R, Meyer, E, Negrin, R, Rezvani, A, Shizuru, JA, Sidana, S, Egeler, E, Mavroukakis, SA, Tunuguntla, R, Gkitsas-Long, N, Retherford, A, Brown, AK, Gramstrap-Petersen, AL, Ibañez, RM, Feldman, S, Miklos, D, Mackall, C, Davis, KL, Frank, MJ, Ramakrishna, S, Muffly, LS. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL. Leukemia 38(5):963-968, 2024. e-Pub 2024. PMID: 38491306.
- Barrozo, ER, Seferovic, MD, Hamilton, MP, Moorshead, DN, Jochum, MD, Do, T, O'Neil, DS, Suter, MA, Aagaard, KM. Zika virus co-opts microRNA networks to persist in placental niches detected by spatial transcriptomics. American journal of obstetrics and gynecology 230(2):251.e1-251.e17, 2024. e-Pub 2024. PMID: 37598997.
- Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng W, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes A, Miklos D, Mackall C, Muffly L. A Phase 1 Clinical Trial of Recombinant, PEGylated IL-15 (NKTR-255) combined with CD19-22 CAR-T Cell Therapy for Refractory B-ALL. Blood. e-Pub 2024.
- Hamilton MP, Sworder BJ, Alig SK, Good Z, Boegeholz J, Schroers-Martin J, Tamaresis J, Esfahani MS, Lu Y, Olsen M, Liu CL, Ehlinger Z, Desai M, Liu-Fei F, Muffly LS, Negrin RS, Arai S, Johnston L, Lowsky R, Meyer EH, Rezvani AR, Shizuru J, Weng W, Shiraz P, Sidana S, Bharadwaj S, Smith M, Dahiya S, Sahaf B, Diehn M, Frank MJ, Mackall CL, Kurtz DM, Miklos DB, Alizadeh AA. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Blood 142(1):360, 2023. e-Pub 2023.
- Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Huttmann A, Hanoun C, Duhrsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41(1):210-225.e5, 2023. e-Pub 2023. PMID: 36584673.
- Good Z, Spiegel JY, Sahaf B, Malipatlolla MB, Ehlinger ZJ, Kurra S, Desai MH, Reynolds WD, Wong Lin A, Vandris P, Wu F, Prabhu S, Hamilton MP, Tamaresis JS, Hanson PJ, Patel S, Feldman SA, Frank MJ, Baird JH, Muffly L, Claire GK, Craig J, Kong KA, Wagh D, Coller J, Bendall SC, Tibshirani RJ, Plevritis SK, Miklos DB, Mackall CL. Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy. Nat Med 28(9):1860-1871, 2022. e-Pub 2022. PMID: 36097223.
- Saha PK, Hamilton MP, Rajapakshe K, Putluri V, Felix JB, Masschelin P, Cox AR, Bajaj M, Putluri N, Coarfa C, Hartig SM. miR-30a targets gene networks that promote browning of human and mouse adipocytes. Am J Physiol Endocrinol Metab 319(4):E667-E677, 2020. e-Pub 2020. PMID: 32799658.
- . The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
- Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshoj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzos A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhayay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uuskula-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, Lopez-Bigas N, Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578(7793):102-111, 2020. e-Pub 2020. PMID: 32025015.
- Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzos A, Herrmann C, Lin Maruvka YE, Shen C, Amin SB, Bandopadhayay P, Bertl J, Boroevich KA, Busnaovich J, carlevaro- Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, LI Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sievrtling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, UUskula-Reimans L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawerence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MS, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell PJ, Lopez-Bigas N. PCAWG Drivers and Functional Interpretation Working Group. Nature 578(7793):102-111. e-Pub 2020.
- Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene 38(28):5700-5724, 2019. e-Pub 2019. PMID: 31043708.
- Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SE. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab 1(1):70-85, 2019. e-Pub 2019. PMID: 31198906.
- Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM. miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes 67(12):2541-2553, 2018. e-Pub 2018. PMID: 30002134.
- Okholm TLH, Nielsen MM, Hamilton MP, Christensen LL, Vang S, Hedegaard J, Hansen TB, Kjems J, Dyrskjot L, Pedersen JS. Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer. NPJ Genom Med 2:36, 2017. e-Pub 2017. PMID: 29263845.
- Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, Lund AH, Vang S, Stribolt K, Madsen MR, Laurberg S, McGuire SE, Orntoft TF, Andersen CL. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol 10(8):1266-82, 2016. e-Pub 2016. PMID: 27396952.
- Hamilton MP, Rajapakshe KI, Bader DA, Cerne JZ, Smith EA, Coarfa C, Hartig SM, McGuire SE. The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia 18(6):356-70, 2016. e-Pub 2016. PMID: 27292025.
- Hartig SM, Hamilton MP, Bader DA, McGuire SE. Trends in Endocrinology and Metabolism 26(12):733-45. e-Pub 2015.
- Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Borresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6):863-879, 2014. e-Pub 2014. PMID: 25490449.
- Hamilton MP, Rajapakshe K, Hartig SM, Reva B, McLellan MD, Kandoth C, Ding L, Zack TI, Gunaratne PH, Wheeler DA, Coarfa C, McGuire SE. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun 4:2730, 2013. e-Pub 2013. PMID: 24220575.
- Hamilton MP, Gore MO, Ayers CR, Xinyu Wu, McGuire DK, Scherer PE. Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diab Vasc Dis Res 8(3):190-4, 2011. e-Pub 2011. PMID: 21555334.
- Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 150(12):5262-72, 2009. e-Pub 2009. PMID: 19819942.
- Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-Phelps K, Scherer PE. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58(9):1961-70, 2009. e-Pub 2009. PMID: 19581422.
Review Articles
- Hamilton, MP, Miklos, D. Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma. Hematology/Oncology Clinics of North America 37(6):1053-1075, 2023. e-Pub 2023. PMID: 37349153.
- Hartig SM, Hamilton MP, Bader DA, McGuire SE. The miRNA Interactome in Metabolic Homeostasis. Trends Endocrinol Metab 26(12):733-745, 2015. e-Pub 2015. PMID: 26492831.
Other Articles
- Hamilton M, Weinstein JN, Collisson EA, Mills GB, Mills Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM The Cancer Genome Atlas Research Network. Nat Genet 45(10):1113-20, 2013. PMID: 24071849.
Patient Reviews
CV information above last modified September 30, 2025